Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis.
Twenty-nine patients, aged 11-79 years (mean, 50 years), with Lyme neuroborreliosis, facial nerve palsy, and meningitis were treated with oral doxycycline (daily dose, 200-400 mg) for 9-17 days in a prospective, nonrandomized study. Facial paresis was bilateral in eight (28%) of the 29 patients. Twenty-six patients (90%) recovered without sequelae within 6 months, while three of the patients with bilateral facial palsy at admission had remaining paresis at follow-up. In five patients, contralateral facial paresis developed 1-12 days after initiation of therapy, and two patients were retreated with antibiotics. Posttreatment examinations of cerebrospinal fluid showed a marked decrease of inflammatory cells and protein concentrations compared with pretreatment levels in all followed up patients. The favorable clinical outcome agrees with findings of other reports on intravenous antibiotic therapy for Lyme disease-associated meningitis with facial palsy. Our conclusion is that oral doxycycline is an effective and convenient therapy for Lyme disease-associated facial palsy.
Dotevall
L
L
Department of Infectious Diseases, Institute of Internal Medicine, Göteborg University, Sweden. leif.dotevall@medfak.gu.se
Hagberg
L
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000097:blood; D015748:Borrelia burgdorferi Group / Q000276:immunology; D002648:Child; D004318:Doxycycline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005158:Facial Paralysis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008193:Lyme Disease / Q000134:cerebrospinal fluid / Q000150:complications / Q000188:drug therapy*; D016920:Meningitis, Bacterial / Q000188:drug therapy*; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D004318:Doxycycline